Relationship of Initial Total Count of White Blood Cell with Post-Induction MRD in Children with Acute Lymphoblastic Leukaemia

Yesmin Tanjin Jahan(1), Zohora Jameela Khan(2), Mehnaz Akter(3), Zannat Ara(4), Rezwana Refat(5), S M Rezanur Rahman(6)
(1) Sir Salimullah Medical College, Dhaka, Bangladesh
(2) Dhaka Medical College, Dhaka, Bangladesh
(3) Dhaka Medical College, Dhaka, Bangladesh
(4) Dhaka Medical College, Dhaka, Bangladesh
(5) Dhaka Medical College, Dhaka, Bangladesh
(6) Dhaka Medical College, Dhaka, Bangladesh

Abstract

Background: Minimal Residual Disease (MRD) following chemotherapy is one of the strongest independent prognostic markers for Acute Lymphoblastic Leukaemia (ALL). Patients with detectable MRD have an increased risk of relapse. There is significant relationship of MRD with other prognostic factors. But this relationship has not been fully evaluated in paediatric patients with ALL. So, the aim of this study is to determine the relationship of initial total count of WBC with MRD at the end of induction. Methodology: This prospective cross-sectional study was conducted in the Department of Paediatric Haematology & Oncology, Dhaka Medical College Hospital (DMCH), from May 2022 to April 2023. A total of thirty children diagnosed with ALL of both sexes between 1 and 19 years who received induction chemotherapy were included in this study. MRD was done at D29 of induction from bone marrow by reverse transcription polymerase chain reaction (RT-PCR) method. Results: This study found that 33.3% patient developed positive MRD. The study showed that significant positive correlation between the initial total count of WBC and MRD level. The analysis also showed a significant relationship between high-risk group, patients receiving regimen B and M3 category bone marrow with MRD (p<0.001). Conclusion: There is significant positive correlation between the initial total count of WBC and MRD level. There is also a significant association with post induction MRD positivity with high-risk group, use of regimen B and patients with M3 marrow.

Full text article

Generated from XML file

References

Park HJ, Moon EK, Yoon JY, et al. Incidence and Survival of Childhood Cancer in Korea. Cancer Res Treat. 2016 Jul;48(3):869-82. doi: 10.4143/crt.2015.290. Epub 2016 Jan 21. PMID: 26790965; PMCID: PMC4946351.

George P, Hernandez K, Hustu O, et al. A study of "total therapy" of acute lymphocytic leukemia in children. J Pediatr. 1968 Mar;72(3):399-408. doi: 10.1016/s0022-3476(68)80217-3. PMID: 5237796.

Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477-89.

Bruggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Hematology. 2017;1:13-21. doi: 10.1182/asheducation-2017.1.13

Judith FM, Karen RR, Philip S, et al. Acute Lymphoblastic Leukemia. In: Pizzo PA, Poplack DG. (ed) Principles and Practice of Pediatric Oncology. 6th edition. Wolters Kluwer Press, Philadelphia; 2015. p.543-48.

Bartram J, Patel B, Fielding AK. Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement. Semin Hematol. 2020;57:142-148.

Kruse A, Abdel-Azim N, Kim HN, et al. Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia. Int J Mol Sci. 2020 Feb 5;21(3):1054. doi: 10.3390/ijms21031054. PMID: 32033444; PMCID: PMC7037356.

Tufekçi O, Evim MS, Guneş AM, et al. Assessment of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: A Multicenter Study From Turkey. J Pediatr Hematol Oncol. 2022 Mar 1;44(2):e396-e402. doi: 10.1097/MPH.0000000000002419. PMID: 35129146.

Scrideli CA, Assumpção JG, Ganazza MA, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica. 2009 Jun;94(6):781-9. doi: 10.3324/haematol.2008.003137. PMID: 19483156; PMCID: PMC268856.

Rocha JMC, Xavier SG, Souza MEL, et al. Current strategies for the detection of minimal residual diseas in childhood acute lymphoblastic leukemia. Mediterr. J. Hematol. Infect. Dis. 2016;8:e2016024. doi: 10.4084/mjhid.2016.024.

Carroll WL, Bhatla T. Acute Lymphoblastic Leukaemia. In: Lanzkowsky, P, Lipton JM, Fish JD. (ed) Lanzkowsky’s manual of paediatric hematology and oncology, 7th edition. Academic Press; 2021. p.374-78.

Coustan-Smith E, Sancho J, Hancock ML, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood. 2000;96(8):2691-2696.

Borowitz MJ, Pullen DJ, Shuster JJ, et al. Minimal residual disease detection in childhood precursor–B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children’s Oncology Group study. Leukemia. 2003;17(8):1566-1572. doi: 10.1038/sj.leu.2403001.

Pawinska-Wasikowska K, Bukowska-Strakova K, Surman M, et al. Go with the flow-early assessment of measurable residual disease in children with acute lymphoblastic leukemia treated according to ALL IC-BFM2009. Cancers (Basel). 2022 Oct 30;14(21):5359. doi: 10.3390/cancers14215359. PMID: 36358778; PMCID: PMC9653819.

Meraj F, Jabbar N, Nadeem K, et al. Minimal residual disease in childhood B Lymphoblastic Leukaemia and its correlation with other risk factors. Pak J Med Sci. 2020;36(1):S20-S26. doi: https://doi.org/10.12669/pjms.36.ICON-Suppl.1721.

Gaipa G, Basso G, Biondi A, et al. Detection of minimal residual disease in paediatric acute lymphoblastic leukaemia. Cytometry B Clin Cytom. 2013;84(6):359-69. doi: 10.1002/cyto.b.21101. Epub 2013 Jun 26. PMID: 2375710.

Qin X, Zhang MY, Liu WJ. Application of minimal residual disease monitoring in pediatric patients with acute lymphoblastic leukemia. Eur Rev Med Pharmacol Sci. 2018 Oct; 22(20):6885-6895. doi: 10.26355/eurrev_201810_16158. PMID: 30402854.

Thorn I, Forestier E, Botling J, et al. Minimal residual disease assessment in childhood acute lymphoblastic leukaemia a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry. Br J Haematol. 2011;152(6):743-53. doi: 10.1111/j.1365-2141.2010.08456.x. Epub 2011 Jan 20. PMID: 2125097.

Campana D, Pui CH. Detection of minimal residual disease in acute leukaemia: methodologic advances and clinical significance. Blood. 1995;85:1416-34.

Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol. 2012;30:1663-9.

Scrideli CA, Assumpção JG, Ganazza MA, et al. A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups. Haematologica. 2009 Jun;94(6):781-9. doi: 10.3324/haematol.2008.003137. PMID: 19483156; PMCID: PMC2688569.

Campana D. Flow-cytometry—based studies of minimal residual disease in children with acute lymphoblastic leukaemia. Leukaemia and Lymphoma: Springer. 2003. p.21-36.

Yeoh AE, Ariffin H, Chai EL, et al. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukaemia: results from the Malaysia-Singapore acute lymphoblastic leukaemia 2003 study. J Clin Oncol. 2012;30:2384-92.

Lee JW, Cho B. Prognostic factors and treatment of pediatric acute lymphoblastic leukemia. Korean J Pediatr. 2017 May;60(5):129-137. doi: 10.3345/kjp.2017.60.5.129. Epub 2017 May 31. PMID: 28592975; PMCID: PMC5461276.

Jovanovska A, Martinova K, Kocheva S, et al. Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia. Open Access Maced J Med Sci. 2019 Sep 14;7(17):2818-2823. doi: 10.3889/oamjms.2019.752. PMID: 31844443; PMCID: PMC6901875.

Authors

Yesmin Tanjin Jahan
yesmin.048586@gmail.com (Primary Contact)
Zohora Jameela Khan
Mehnaz Akter
Zannat Ara
Rezwana Refat
S M Rezanur Rahman
Author Biographies

Yesmin Tanjin Jahan, Sir Salimullah Medical College, Dhaka

Assistant Professor, Department of Pediatric Hematology and Oncology, Sir Salimullah Medical College & Mitford Hospital, Dhaka. Contact No: +8801799389391, E-mail: yesmin.048586@gmail.com

Zohora Jameela Khan, Dhaka Medical College, Dhaka

Professor, Department of Pediatric Hematology & Oncology, Dhaka Medical College Hospital, Dhaka

Mehnaz Akter, Dhaka Medical College, Dhaka

Assistant Professor, Department of Paediatric Hematology & Oncology, Dhaka Medical College Hospital, Dhaka

Zannat Ara, Dhaka Medical College, Dhaka

Assistant Professor, Department of Pediatric Hematology & Oncology, Dhaka Medical College Hospital, Dhaka

Rezwana Refat, Dhaka Medical College, Dhaka

Registrar, Department of Pediatric Hematology & Oncology, Dhaka Medical College Hospital, Dhaka

S M Rezanur Rahman, Dhaka Medical College, Dhaka

Assistant Professor, Department of Pediatric Hematology & Oncology, Dhaka Medical College Hospital, Dhaka

1.
Jahan YT, Khan ZJ, Akter M, Ara Z, Refat R, Rahman SMR. Relationship of Initial Total Count of White Blood Cell with Post-Induction MRD in Children with Acute Lymphoblastic Leukaemia. Haematol J Bangladesh [Internet]. 2023 Dec. 31 [cited 2024 Apr. 17];7(2):74-81. Available from: https://journal.hematologybd.org/index.php/haematoljbd/article/view/113

Article Details

How to Cite

1.
Jahan YT, Khan ZJ, Akter M, Ara Z, Refat R, Rahman SMR. Relationship of Initial Total Count of White Blood Cell with Post-Induction MRD in Children with Acute Lymphoblastic Leukaemia. Haematol J Bangladesh [Internet]. 2023 Dec. 31 [cited 2024 Apr. 17];7(2):74-81. Available from: https://journal.hematologybd.org/index.php/haematoljbd/article/view/113

Risk Prediction of Febrile Neutropenia in Children with Acute Lymphoblastic Leukemia

Lutfor Rahman Mollah, Amirul Morshed Khasru, Md. Bani Yeamin, Zannat Ara, Tanvir Ahamed,...